Valeant Stock Set to Continue Recovery
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is slowly but surely moving higher. Indeed, if we are to give credence to its CEO Joseph Papa, Valeant stock is poised for a nice recovery by the start of 2017. The bullish argument draws from the fact that Valeant confirmed a prediction made last August 9. Namely, that the company would meet a revenue target of $9.9 billion to $10.1 billion. (Source: ".
Den vollständigen Artikel lesen ...
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is slowly but surely moving higher. Indeed, if we are to give credence to its CEO Joseph Papa, Valeant stock is poised for a nice recovery by the start of 2017. The bullish argument draws from the fact that Valeant confirmed a prediction made last August 9. Namely, that the company would meet a revenue target of $9.9 billion to $10.1 billion. (Source: ".
Den vollständigen Artikel lesen ...